Overall Status

Completed (2)

Recruiting (1)

Phase

early phase 1 (1)

phase 1 (1)

Sponsor

Jagiellonian University (1)

Luye Pharma Group Ltd. (1)

University of Chicago (1)

Collaborator

Intervention

change of optic nerve sheath diameter (1)

ethanol (1)

ly03010 156 mg treatment group, deltoid (1)

ly03010 156 mg treatment group, gluteal (1)

ly03010 351 mg treatment group, deltoid (1)

ly03010 351 mg treatment group, gluteal (1)

placebo (1)

Study Documents

Intervention Type

drug (2)

diagnostic test (1)

other (1)

Funder Type

Other (2)

Industry (1)

Study Type

Interventional (2)

Observational (1)

central nervous system depression

Showing 1 - 3 of 3

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

LAST UPDATED

Schizophrenia, Psychotic Disorders, Mood Disorders Trial in United States (LY03010 156 mg treatment group, deltoid, LY03010 156

Recruiting

Schizophrenia
+11 more

LY03010 156 mg treatment group, deltoid
+3 more

Little Rock, Arkansas
+8 more

Apr 11, 2022

Alcohol Drinking, Drinking Behavior, Physiological Effects of Drugs Trial in Chicago (Ethanol, Placebo)

Completed

Alcohol Drinking
+3 more

Ethanol
Placebo

Chicago, Illinois

University of Chicago

Jan 20, 2021

Optic Nerve Sheath Diameter in in Patients Operated for

Completed

Anaesthetic Complication Neurological
Central Nervous System Depression

Change of Optic Nerve Sheath Diameter

Kraków, Poland

University Hospital in Cracow

Feb 20, 2020